Evaluation of combinations of bedaquiline, moxifloxacin,...

In the News

IHI at the first Malaria World Congress in Melbourne

(Melbourne) Ifakara Health Institute (IHI) was represented by three scientists to the inaugural Malaria World Congress in Melbourne, Australia. Research scientists, Dr. Gerry Killeen and Nancy Matowo took to the …

IHI researcher Nancy on Australian radio SBS

(Melbourne) Ifakara Health Institute (IHI) Research Scientist Nancy Matowo recently was invited to a 26-minute radio interview with the SBS, a Swahili Australian radio, to share her research work and …

Recent Projects

Sustainable, Healthy, Learning Cities and Neighbourhoods

The Sustainable, Healthy, Learning Cities and Neighbourhoods is an exciting project in which IHI works with a consortium of partners from Asia and Africa to 1) develop capacity for improved …

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

A phase 2 Open‐Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide during 8 weeks of treatment in Adult Subjects with Newly Diagnosed Drug‐Sensitive or Multi Drug‐ Resistant, Smear‐Positive Pulmonary Tuberculosis.

NC005 is a multicenter phase 2 Open‐Label Partially Randomized Trial to evaluate the efficacy, safety and tolerability of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide during 8 weeks of treatment in Adult Subjects with Newly Diagnosed Drug‐Sensitive or Multi Drug‐ Resistant, Smear‐Positive Pulmonary Tuberculosis. The primary objective of the study is to assess the mycobactericidal activity of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide regimens during 8 weeks of treatment. IHI enrolled only drug sensitive TB participants, whereby 31 participants were enrolled. Participants were randomized to receive either bedaquilline 400mg (J) (loading dose/t.i.w.), Pa824 200mg (Pa) and Pyrazinamide 1500mg (Z); or J (200mg)PaZ; or HRZE. The HRZE treatment arm is included as a control for the drug‐sensitive treatments. Enrollment and follow up complemented in February 2016 and currently participants are on a six monthly telephonic survival follow up until early 2018.

Lead Scientists:

Frederick Haraka

Francis Mhimbira

Partners

Mbeya Medical Research Centre-NIMR
TB Alliance
Swiss Tropical and Public Health Insitute

Funders

Global Alliance for TB drug development (TB Alliance)

Projects Location

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016